Clinical whole‐genome sequencing in cancer diagnosis. Issue 11 (26th April 2022)

• Record Type: Journal Article
• Authors: Hou, Ying‐Chen C.; Neidich, Julie A.; Duncavage, Eric J.; Spencer, David H.; Schroeder, Molly C.
• Other Names: Scott Stuart A. guestEditor.; Wang Kai guestEditor.; Spinner Nancy B. guestEditor.
• Is Part Of: Human mutation. Volume 43:Issue 11(2022)
• Page Start: 1519
• Page End: 1530
• Publication Date: 2022-04-26
• Subjects: cancer -- molecular diagnostic testing -- whole‐genome sequencing; Human chromosome abnormalities -- Periodicals; Mutation (Biology) -- Periodicals; 616.04205
• DOI: 10.1002/humu.24381
• Languages: English
• ISSNs: 1059-7794

Abstract

Abstract: Characterizing the genomic landscape of cancers is a routine part of clinical care that began with the discovery of the Philadelphia chromosome and has since coevolved with genomic technologies. Genomic analysis of tumors at the nucleotide level using DNA sequencing has revolutionized the understanding of cancer biology and identified new molecular drivers of disease that have led to therapeutic advances and improved patient outcomes. However, the application of next‐generation sequencing in the clinical laboratory has generally been limited until very recently to targeted analysis of selected genes. Recent technological innovations and reductions in sequencing costs are now able to deliver the long‐promised goal of tumor whole‐genome sequencing as a practical clinical assay.